-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Benzinga·12/19/2025 14:45:11
Listen to the news
Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.